Pharmacology of moclobemide.
Moclobemide is a reversible inhibitor of monoamine oxidase (MAO) with clear preference for the A type (so-called RIMA). The enzyme inhibition shows complex kinetics, and the molecular mechanism of interaction with the enzyme is not yet clear. Moclobemide increases the extracellular concentration of the monoamines in rat brain and decreases the level of their metabolites. Neither a loss nor a cumulation of activity has been observed after chronic treatment. Reversibility of MAO-A inhibition was demonstrated in vitro as well as in vivo. In various animal behavioral models, in particular in a novel model of stress-induced anhedonia, moclobemide was as effective as standard antidepressants. Moclobemide improves cognitive functions that are impaired in experimental situations. A neuroprotective action is seen in rats subjected to transient global ischemia/-hypoxia. Moclobemide lacks anticholinergic and other effects and only slightly increases the pressor effect of orally administered tyramine. Possible links between MAO-A inhibition and the various effects of moclobemide on brain function are discussed.
Haefely
W
W
Pharma Division, F. Hoffmann-La Roche Ltd., Basel, Switzerland.
Burkard
W P
WP
Cesura
A
A
Colzi
A
A
Kettler
R
R
Lorez
H P
HP
Martin
J R
JR
Moreau
J L
JL
Richards
J G
JG
Schaffner
R
R
D000818:Animals; D000928:Antidepressive Agents / Q000494:pharmacology; D001549:Benzamides / Q000494:pharmacology*; D004357:Drug Synergism; D006801:Humans; D020912:Moclobemide; D008996:Monoamine Oxidase Inhibitors / Q000494:pharmacology*; D014439:Tyramine / Q000494:pharmacology
D000928:Antidepressive Agents; D001549:Benzamides; D008996:Monoamine Oxidase Inhibitors; D020912:Moclobemide; D014439:Tyramine